Marcella Sarzotti-Kelsoe
Research Professor of Integrative Immunobiology
•I direct a Global Quality Assurance Program, which I developed and pioneered here at Duke University, to oversee compliance with Good Clinical Laboratory Practice Guidelines in three HIV vaccine trial networks (CHAVI, CAVD, Duke HVTN, EQAPOL, Duke VTEU) involving domestic and international laboratory sites.
•I also direct a Global Proficiency Testing Program for laboratories testing for neutralizing antibody function in individuals infected with HIV or vaccinated against HIV. The Program was launched in 2009.
•I provide assistance and oversight for endpoint assay standardization, qualification and validation, as well as for the QSU of the GMP facility at DHVI, which will manufacture HIV vaccine products for first-in-man Phase I trials.
Past Basic Research
•Development of T cell responses in neonates.
•Neonatal T cell receptor Vβ repertoire diversity in the peripheral T cell pool.
•The role of heat shock protein, as a natural adjuvant, at eliciting innate and adaptive immune responses.
•Development of the T cell receptor repertoire in naïve, immunodeficient infants, given bone marrow or thymic transplantation.
•Thymic output, T cell diversity and T cell function in long-term human SCID chimeras.
•Telomere length in T cells from SCID chimeras.
Current Appointments & Affiliations
- Research Professor of Integrative Immunobiology, Integrative Immunobiology, Basic Science Departments 2013
- Associate Professor in Surgery, Surgery, Clinical Science Departments 2020
- Member of the Duke Human Vaccine Institute, Duke Human Vaccine Institute, Institutes and Centers 2006
Contact Information
- 2812 Erwin Rd., Suite 301, Durham, NC 27705
- DUMC Box 102800, Durham, NC 27710
-
marcella.kelsoe@duke.edu
(919) 684-6373
-
ASIST Office, School of Medicine
-
Immunology Profile
- Background
-
Education, Training, & Certifications
- D.R., University of Turin (Italy) 1986
- Ph.D., University of Turin (Italy) 1980
-
Previous Appointments & Affiliations
- Associate Professor in Surgery, Surgery, Clinical Science Departments 2013 - 2020
- Associate Research Professor of Immunology, Integrative Immunobiology, Basic Science Departments 2005 - 2012
- Assistant Professor in Surgery, Surgery, Clinical Science Departments 2009 - 2012
- Assistant Research Professor of Immunology, Integrative Immunobiology, Basic Science Departments 1998 - 2005
- Instructor, Temporary of Immunology, Integrative Immunobiology, Basic Science Departments 1998
- Expertise
-
Subject Headings
-
Global Scholarship
- Research
-
Selected Grants
- Protein Production Facility awarded by Bill and Melinda Gates Foundation 2022 - 2026
- CIVICS A - Option 21A Equitable Adjustment awarded by National Institutes of Health 2022 - 2025
- CIVICS A - Option 21A awarded by National Institute of Allergy and Infectious Diseases 2021 - 2025
- Neutralizing Antibody Assessment for SARS-CoV-2 Vaccine Trials awarded by Vaccine Company, Inc. 2023 - 2025
- CISA COVID Flu Immunogenicity awarded by Centers for Disease Control and Prevention 2022 - 2024
- CISA COVID Peds Immunogenicity awarded by Centers for Disease Control and Prevention 2022 - 2024
- CISA Maternal COVID Immunogenicity awarded by Centers for Disease Control and Prevention 2022 - 2024
- EQAPOL - Years 2017 to 2024 - BASE awarded by National Institutes of Health 2017 - 2024
- Moderna mRNA1275 P205 Trial Neutralizing Antibody Assessment awarded by Moderna Therapeutics, Inc. 2021 - 2024
- A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled, Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effe awarded by Moderna Therapeutics, Inc. 2021 - 2024
- HVTN LC awarded by Fred Hutchinson Cancer Center 2022 - 2023
- HVTN Laboratory Center: Phase 1 PF awarded by Fred Hutchinson Cancer Center 2022 - 2023
- HVTN Laboratory Center: 702 PF awarded by Fred Hutchinson Cancer Center 2020 - 2023
- CIVICS Component A - Option 3 awarded by National Institutes of Health 2019 - 2023
- NIAID Virology Quality Assurance - Year 4 Option 3 awarded by National Institutes of Health 2019 - 2023
- A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years awarded by Moderna Therapeutics, Inc. 2021 - 2023
- Moderna mRNA-1273 P201 (Part B) Trial Neutralizing Antibody Assessment awarded by Moderna Therapeutics, Inc. 2021 - 2023
- Defining and Redirecting Influenza Immunity After Imprinting awarded by Boston Children's Hospital 2021 - 2023
- A Phase 3b, Open-Label, Safety and Immunogenicity Study of SARS-CoV-2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls awarded by Moderna Therapeutics, Inc. 2021 - 2023
- Surgical Critical Care Initiative (SC2I): Civilian application of military decision support tools for critically injured patients. awarded by Henry M. Jackson Foundation 2021 - 2023
- Neutralizing Antibody Response Assessment for a Phase 2/3 Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccin awarded by Moderna Therapeutics, Inc. 2021 - 2023
- A phase 2 randomized, open-label, parallel group study to assess the immunogenicity, safety, and tolerability of Moderna mRNA-1273 vaccine administered with casirivimab+imdevimab in healthy adult volunteers awarded by Regeneron Pharmaceuticals, Inc. 2021 - 2023
- HVTN 705 Case Control Janssen awarded by Fred Hutchinson Cancer Center 2021 - 2022
- CoVPN 3001 A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine awarded by Fred Hutchinson Cancer Center 2022
- CoVPN 3003 A Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older awarded by Seattle Cancer Care Alliance 2022
- CoVPN 3005: Efficacy, Immunogenicity, and Safety of Two SARS-CoV-2 Recombinant Protein Vaccines with Adjuvant in Adults 18 Years of Age and Older awarded by Seattle Cancer Care Alliance 2022
- CoVPN 3008 Multi-Center, Randomized, Efficacy Study of Early vs Deferred Vaccination with COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern awarded by Fred Hutchinson Cancer Center 2022
- CoVPN 5001 A Prospective Study of Acute Immune Responses to SARS-CoV-2 Infection awarded by Fred Hutchinson Cancer Center 2022
- HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals awarded by Fred Hutchinson Cancer Center 2022
- Protein Production Facility awarded by Bill and Melinda Gates Foundation 2016 - 2022
- A PHASE 2a, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, DOSE-CONFIRMATION STUDY TO EVALUATE THE SAFETY, REACTOGENICITY, AND IMMUNOGENICITY OF MRNA-1273 SARS-COV-2 VACCINE IN ADULTS AGED 18 YEARS A awarded by Moderna Therapeutics, Inc. 2021 - 2022
- Neutralizing antibody assessment for EID 030 SARS-CoV-2 Vaccine Phase I trial awarded by Henry M. Jackson Foundation 2021 - 2022
- CoVPN 3008 Multi-Center, Randomized, Efficacy Study of Early vs Deferred Vaccination with COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern awarded by Fred Hutchinson Cancer Research Center 2020 - 2022
- HVTN Laboratory Center: Phase 1 PF awarded by Fred Hutchinson Cancer Research Center 2020 - 2022
- CoVPN 5001 A prospective study of acute immune responses to SARS-CoV2 infection - LAB awarded by Fred Hutchinson Cancer Research Center 2020 - 2022
- HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals awarded by Fred Hutchinson Cancer Research Center 2020 - 2022
- HVTN 705 Pilot awarded by Fred Hutchinson Cancer Research Center 2020 - 2021
- HVTN Laboratory Center: P5 PF awarded by Fred Hutchinson Cancer Research Center 2020 - 2021
- Immunologic control of HIV-1 through combination bNAbs and biologics awarded by Rockefeller University 2020 - 2021
- Sc2i awarded by Henry M. Jackson Foundation 2020 - 2021
- HVTN Laboratory Center: HVTN Phase 1 awarded by Fred Hutchinson Cancer Research Center 2015 - 2020
- HVTN Laboratory Center: HVTN 118 awarded by Fred Hutchinson Cancer Research Center 2006 - 2020
- SC2i awarded by Henry M. Jackson Foundation 2014 - 2020
- HVTN TB Correlates Pilot Studies Supplement awarded by Fred Hutchinson Cancer Research Center 2019
- HVTN Laboratory Center: HVTN 117 awarded by Fred Hutchinson Cancer Research Center 2017 - 2018
- HVTN Laboratory Center: HVTN 118 awarded by Fred Hutchinson Cancer Research Center 2017 - 2018
- HIV Vaccine Trials Network: LC P5 PF awarded by Fred Hutchinson Cancer Research Center 2015 - 2018
- HVTN - A004 awarded by Fred Hutchinson Cancer Research Center 2015 - 2018
- Nonhuman Primate Core-Option 6 awarded by National Institutes of Health 2012 - 2018
- EQAPOL Option 47 awarded by National Institutes of Health 2011 - 2017
- EQAPOL - 2016 to 2017 - Option 6 - BASE awarded by National Institutes of Health 2010 - 2017
- EQAPOL - Option 48 - 2016 to 2017 - LUMINEX awarded by National Institutes of Health 2010 - 2017
- EQAPOL Option 5 awarded by National Institutes of Health 2010 - 2017
- Animal Models of Infectious Diseases Part A awarded by National Institutes of Health 2010 - 2017
- HIV Vaccine Trials Network: LC P5 PF awarded by Fred Hutchinson Cancer Research Center 2014 - 2015
- LC: HIV Vaccine Trials Network: Phase 1 PF awarded by Fred Hutchinson Cancer Research Center 2014 - 2015
- IQA Option 4 awarded by National Institutes of Health 2007 - 2014
- Production of HIV-1 Envs #2 awarded by Foundation for the National Institutes of Health 2012 - 2013
- Mechanisms of Allogeneic Stem Cell Education in SCID awarded by National Institutes of Health 1999 - 2012
- Role Of Surfactant In Innate and Adaptive Immunity awarded by National Institutes of Health 2001 - 2011
- Dose Study of Thymus Transplantation, IND 9836 awarded by Food and Drug Administration 2005 - 2008
- Thymic Transplantation in Complete DiGeorge Syndrome awarded by National Institutes of Health 1999 - 2004
- Memory T Cell Induction In Neonates By Viral Vaccines awarded by National Institutes of Health 1996 - 2002
-
External Relationships
- QualCon, Inc., a consulting company
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Gilbert, Peter B., David C. Montefiori, Adrian B. McDermott, Youyi Fong, David Benkeser, Weiping Deng, Honghong Zhou, et al. “Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.” Science 375, no. 6576 (January 7, 2022): 43–50. https://doi.org/10.1126/science.abm3425.Full Text Link to Item
-
Huang, Yunda, Oleg Borisov, Jia Jin Kee, Lindsay N. Carpp, Terri Wrin, Suqin Cai, Marcella Sarzotti-Kelsoe, et al. “Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation.” Scientific Reports 11, no. 1 (December 2021): 23921. https://doi.org/10.1038/s41598-021-03154-6.Full Text
-
Huang, Yunda, Oleg Borisov, Jia Jin Kee, Lindsay N. Carpp, Terri Wrin, Suqin Cai, Marcella Sarzotti-Kelsoe, et al. “Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation.” Medrxiv, September 14, 2021. https://doi.org/10.1101/2021.09.09.21263049.Full Text Link to Item
-
Hosseinipour, Mina C., Craig Innes, Sarita Naidoo, Philipp Mann, Julia Hutter, Gita Ramjee, Modulakgotla Sebe, et al. “Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein.” Clin Infect Dis 72, no. 1 (January 23, 2021): 50–60. https://doi.org/10.1093/cid/ciz1239.Full Text Link to Item
-
Wesley, Martina S., Kelvin T. Chiong, Kelly E. Seaton, Christine A. Arocena, Sheetal Sawant, Jonathan Hare, Kasey Hernandez, et al. “Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS.” Front Immunol 12 (2021): 709994. https://doi.org/10.3389/fimmu.2021.709994.Full Text Link to Item
-
Seaman, Michael S., Miroslawa Bilska, Fadi Ghantous, Amanda Eaton, Celia C. LaBranche, Kelli Greene, Hongmei Gao, et al. “Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bnAbs.” J Immunol Methods 479 (April 2020): 112736. https://doi.org/10.1016/j.jim.2020.112736.Full Text Link to Item
-
Simon, Christian, Rebecca W. Beerman, Jennifer L. Ariansen, Donna Kessler, Ana M. Sanchez, Kindra King, Marcella Sarzotti-Kelsoe, et al. “Implementation of a responsible conduct of research education program at Duke University School of Medicine.” Account Res 26, no. 5 (July 2019): 288–310. https://doi.org/10.1080/08989621.2019.1621755.Full Text Link to Item
-
Dennison, S Moses, Matthew Reichartz, Kelly E. Seaton, Sheetij Dutta, Ulrike Wille-Reece, Adrian V. S. Hill, Katie J. Ewer, et al. “Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with Plasmodium falciparum Circumsporozoite Protein Antigens.” J Immunol 201, no. 4 (August 15, 2018): 1315–26. https://doi.org/10.4049/jimmunol.1800323.Full Text Link to Item
-
Bekker, Linda-Gail, Zoe Moodie, Nicole Grunenberg, Fatima Laher, Georgia D. Tomaras, Kristen W. Cohen, Mary Allen, et al. “Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.” Lancet Hiv 5, no. 7 (July 2018): e366–78. https://doi.org/10.1016/S2352-3018(18)30071-7.Full Text Link to Item
-
Brown, Eric P., Joshua A. Weiner, Shu Lin, Harini Natarajan, Erica Normandin, Dan H. Barouch, Galit Alter, Marcella Sarzotti-Kelsoe, and Margaret E. Ackerman. “Optimization and qualification of an Fc Array assay for assessments of antibodies against HIV-1/SIV.” J Immunol Methods 455 (April 2018): 24–33. https://doi.org/10.1016/j.jim.2018.01.013.Full Text Link to Item
-
Fong, Youyi, Xiaoying Shen, Vicki C. Ashley, Aaron Deal, Kelly E. Seaton, Chenchen Yu, Shannon P. Grant, et al. “Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial.” J Infect Dis 217, no. 8 (March 28, 2018): 1280–88. https://doi.org/10.1093/infdis/jiy008.Full Text Link to Item
-
Schultz, Anke, Anja Germann, Martina Fuss, Marcella Sarzotti-Kelsoe, Daniel A. Ozaki, David C. Montefiori, Heiko Zimmermann, and Hagen von Briesen. “Validation of an automated system for aliquoting of HIV-1 Env-pseudotyped virus stocks.” Plos One 13, no. 1 (2018): e0190669. https://doi.org/10.1371/journal.pone.0190669.Full Text Link to Item
-
Hu, Xintao, Yuanyuan Hu, Chunhong Zhao, Hongmei Gao, Kelli M. Greene, Li Ren, Liying Ma, et al. “Profiling the neutralizing antibody response in chronically HIV-1 CRF07_BC-infected intravenous drug users naïve to antiretroviral therapy.” Sci Rep 7 (April 7, 2017): 46308. https://doi.org/10.1038/srep46308.Full Text Link to Item
-
Permar, Sallie R., Youyi Fong, Nathan Vandergrift, Genevieve G. Fouda, Peter Gilbert, Robert Parks, Frederick H. Jaeger, et al. “Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission.” J Clin Invest 125, no. 7 (July 1, 2015): 2702–6. https://doi.org/10.1172/JCI81593.Full Text Open Access Copy Link to Item
-
Sanchez, Ana M., Wes Rountree, Mark Berrong, Ambrosia Garcia, Alexandra Schuetz, Josephine Cox, Nicole Frahm, et al. “The External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-γ ELISpot) assay.” J Immunol Methods 409 (July 2014): 31–43. https://doi.org/10.1016/j.jim.2014.03.017.Full Text Open Access Copy Link to Item
-
Sarzotti-Kelsoe, Marcella, Leila K. Needham, Wes Rountree, John Bainbridge, Clive M. Gray, Susan A. Fiscus, Guido Ferrari, et al. “The Center for HIV/AIDS Vaccine Immunology (CHAVI) multi-site quality assurance program for cryopreserved human peripheral blood mononuclear cells.” J Immunol Methods 409 (July 2014): 21–30. https://doi.org/10.1016/j.jim.2014.05.013.Full Text Open Access Copy Link to Item
-
Sarzotti-Kelsoe, Marcella, Xiaoju Daniell, Christopher A. Todd, Miroslawa Bilska, Amanda Martelli, Celia LaBranche, Lautaro G. Perez, et al. “Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells.” J Immunol Methods 409 (July 2014): 147–60. https://doi.org/10.1016/j.jim.2014.02.013.Full Text Open Access Copy Link to Item
-
Todd, Christopher A., Ana M. Sanchez, Ambrosia Garcia, Thomas N. Denny, and Marcella Sarzotti-Kelsoe. “Implementation of Good Clinical Laboratory Practice (GCLP) guidelines within the External Quality Assurance Program Oversight Laboratory (EQAPOL).” J Immunol Methods 409 (July 2014): 91–98. https://doi.org/10.1016/j.jim.2013.09.012.Full Text Open Access Copy Link to Item
-
Sarzotti-Kelsoe, Marcella, Robert T. Bailer, Ellen Turk, Chen-li Lin, Miroslawa Bilska, Kelli M. Greene, Hongmei Gao, et al. “Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.” J Immunol Methods 409 (July 2014): 131–46. https://doi.org/10.1016/j.jim.2013.11.022.Full Text Link to Item
-
deCamp, Allan, Peter Hraber, Robert T. Bailer, Michael S. Seaman, Christina Ochsenbauer, John Kappes, Raphael Gottardo, et al. “Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies.” J Virol 88, no. 5 (March 2014): 2489–2507. https://doi.org/10.1128/JVI.02853-13.Full Text Link to Item
-
Todd, C. A., A. M. Sanchez, A. Garcia, T. N. Denny, and M. Sarzotti-Kelsoe. “Implementation of Good Clinical Laboratory Practice (GCLP) guidelines within the External Quality Assurance Program Oversight Laboratory (EQAPOL).” Journal of Immunological Methods 409 (January 1, 2014): 91–98. https://doi.org/10.1016/j.jim.2013.09.012.Full Text Open Access Copy
-
Buckley, Rebecca H., Chan M. Win, Barry K. Moser, Roberta E. Parrott, Elisa Sajaroff, and Marcella Sarzotti-Kelsoe. “Post-transplantation B cell function in different molecular types of SCID.” J Clin Immunol 33, no. 1 (January 2013): 96–110. https://doi.org/10.1007/s10875-012-9797-6.Full Text Open Access Copy Link to Item
-
Hu, Xintao, Kunxue Hong, Chunhong Zhao, Yang Zheng, Liying Ma, Yuhua Ruan, Hongmei Gao, et al. “Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy.” J Gen Virol 93, no. Pt 10 (October 2012): 2267–78. https://doi.org/10.1099/vir.0.043802-0.Full Text Link to Item
-
Diomede, L., S. Nyoka, C. Pastori, L. Scotti, A. Zambon, G. Sherman, C. M. Gray, M. Sarzotti-Kelsoe, and L. Lopalco. “Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.” J Virol 86, no. 8 (April 2012): 4129–38. https://doi.org/10.1128/JVI.06359-11.Full Text Link to Item
-
Todd, Christopher A., Kelli M. Greene, Xuesong Yu, Daniel A. Ozaki, Hongmei Gao, Yunda Huang, Maggie Wang, et al. “Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells.” J Immunol Methods 375, no. 1–2 (January 31, 2012): 57–67. https://doi.org/10.1016/j.jim.2011.09.007.Full Text Link to Item
-
Buckley, R. H., C. M. Win, B. K. Moser, R. E. Parrott, E. Sajaroff, and M. Sarzotti-Kelsoe. “Post-Transplantation B Cell Function in Different Molecular Types of SCID.” Journal of Clinical Immunology, 2012, 1–15.
-
Ozaki, Daniel A., Hongmei Gao, Christopher A. Todd, Kelli M. Greene, David C. Montefiori, and Marcella Sarzotti-Kelsoe. “International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials.” Plos One 7, no. 1 (2012): e30963. https://doi.org/10.1371/journal.pone.0030963.Full Text Link to Item
-
Schultz, Anke, Stefanie Koch, Martina Fuss, Angela S. Mazzotta, Marcella Sarzotti-Kelsoe, Daniel A. Ozaki, David C. Montefiori, Hagen von Briesen, Heiko Zimmermann, and Andreas Meyerhans. “An automated HIV-1 Env-pseudotyped virus production for global HIV vaccine trials.” Plos One 7, no. 12 (2012): e51715. https://doi.org/10.1371/journal.pone.0051715.Full Text Link to Item
-
Sarzotti-Kelsoe, Marcella, Xiaoju G. Daniell, John F. Whitesides, and Rebecca H. Buckley. “The long and the short of telomeres in bone marrow recipient SCID patients.” Immunol Res 49, no. 1–3 (April 2011): 44–48. https://doi.org/10.1007/s12026-010-8192-8.Full Text Link to Item
-
Sarzotti-Kelsoe, M., J. Cox, N. Cleland, T. Denny, J. Hural, L. Needham, D. Ozaki, et al. “P15-05. Evaluation and recommendations on good clinical laboratory practice (GCLP) guidelines for phase I-III HIV vaccine clinical trials.” Retrovirology 6, no. SUPPL. 3 (October 22, 2009). https://doi.org/10.1186/1742-4690-6-S3-P206.Full Text
-
Sarzotti-Kelsoe, Marcella, Chan M. Win, Roberta E. Parrott, Myriah Cooney, Barry K. Moser, Joseph L. Roberts, Gregory D. Sempowski, and Rebecca H. Buckley. “Thymic output, T-cell diversity, and T-cell function in long-term human SCID chimeras.” Blood 114, no. 7 (August 13, 2009): 1445–53. https://doi.org/10.1182/blood-2009-01-199323.Full Text Link to Item
-
Sarzotti-Kelsoe, Marcella, Josephine Cox, Naana Cleland, Thomas Denny, John Hural, Leila Needham, Daniel Ozaki, et al. “Evaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials.” Plos Med 6, no. 5 (May 26, 2009): e1000067. https://doi.org/10.1371/journal.pmed.1000067.Full Text Open Access Copy Link to Item
-
Sarzotti-Kelsoe, Marcella, Josephine Cox, Naana Cleland, Thomas Denny, John Hural, Leila Needham, Daniel Ozaki, et al. “Evaluation and Recommendations on Good Clinical Laboratory Practice Guidelines for Phase I-III Clinical Trials.” Plos Medicine 6, no. 5 (2009). https://doi.org/10.1371/journal.pmed.1000067.Full Text Link to Item
-
Markert, M Louise, Blythe H. Devlin, Marilyn J. Alexieff, Jie Li, Elizabeth A. McCarthy, Stephanie E. Gupton, Ivan K. Chinn, et al. “Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants.” Blood 109, no. 10 (May 15, 2007): 4539–47. https://doi.org/10.1182/blood-2006-10-048652.Full Text Link to Item
-
Roberts, Joseph L., Jens Peter H. Lauritsen, Myriah Cooney, Roberta E. Parrott, Elisa O. Sajaroff, Chan M. Win, Michael D. Keller, et al. “T-B+NK+ severe combined immunodeficiency caused by complete deficiency of the CD3zeta subunit of the T-cell antigen receptor complex.” Blood 109, no. 8 (April 15, 2007): 3198–3206. https://doi.org/10.1182/blood-2006-08-043166.Full Text Link to Item
-
Fadel, Shaza A., Lindsay G. Cowell, Shui Cao, Daniel A. Ozaki, Thomas B. Kepler, Douglas A. Steeber, and Marcella Sarzotti. “Neonate-primed CD8+ memory cells rival adult-primed memory cells in antigen-driven expansion and anti-viral protection.” Int Immunol 18, no. 2 (February 2006): 249–57. https://doi.org/10.1093/intimm/dxh360.Full Text Link to Item
-
He, Min, John K. Tomfohr, Blythe H. Devlin, Marcella Sarzotti, M Louise Markert, and Thomas B. Kepler. “SpA: web-accessible spectratype analysis: data management, statistical analysis and visualization.” Bioinformatics 21, no. 18 (September 15, 2005): 3697–99. https://doi.org/10.1093/bioinformatics/bti600.Full Text Link to Item
-
Kepler, Thomas B., Min He, John K. Tomfohr, Blythe H. Devlin, Marcella Sarzotti, and M Louise Markert. “Statistical analysis of antigen receptor spectratype data.” Bioinformatics 21, no. 16 (August 15, 2005): 3394–3400. https://doi.org/10.1093/bioinformatics/bti539.Full Text Link to Item
-
Markert, M Louise, Marilyn J. Alexieff, Jie Li, Marcella Sarzotti, Daniel A. Ozaki, Blythe H. Devlin, Debra A. Sedlak, et al. “Postnatal thymus transplantation with immunosuppression as treatment for DiGeorge syndrome.” Blood 104, no. 8 (October 15, 2004): 2574–81. https://doi.org/10.1182/blood-2003-08-2984.Full Text Link to Item
-
Baker-LePain, Julie C., Marcella Sarzotti, and Christopher V. Nicchitta. “Glucose-regulated protein 94/glycoprotein 96 elicits bystander activation of CD4+ T cell Th1 cytokine production in vivo.” J Immunol 172, no. 7 (April 1, 2004): 4195–4203. https://doi.org/10.4049/jimmunol.172.7.4195.Full Text Link to Item
-
Markert, M Louise, Marilyn J. Alexieff, Jie Li, Marcella Sarzotti, Daniel A. Ozaki, Blythe H. Devlin, Gregory D. Sempowski, et al. “Complete DiGeorge syndrome: development of rash, lymphadenopathy, and oligoclonal T cells in 5 cases.” J Allergy Clin Immunol 113, no. 4 (April 2004): 734–41. https://doi.org/10.1016/j.jaci.2004.01.766.Full Text Link to Item
-
Markert, M Louise, Marcella Sarzotti, Daniel A. Ozaki, Gregory D. Sempowski, Maria E. Rhein, Laura P. Hale, Francoise Le Deist, et al. “Thymus transplantation in complete DiGeorge syndrome: immunologic and safety evaluations in 12 patients.” Blood 102, no. 3 (August 1, 2003): 1121–30. https://doi.org/10.1182/blood-2002-08-2545.Full Text Link to Item
-
Sarzotti, Marcella, Dhavalkumar D. Patel, Xiaojing Li, Daniel A. Ozaki, Shui Cao, Scott Langdon, Roberta E. Parrott, Katherine Coyne, and Rebecca H. Buckley. “T cell repertoire development in humans with SCID after nonablative allogeneic marrow transplantation.” J Immunol 170, no. 5 (March 1, 2003): 2711–18. https://doi.org/10.4049/jimmunol.170.5.2711.Full Text Link to Item
-
Baker-LePain, Julie C., Marcella Sarzotti, Timothy A. Fields, Chuan-Yuan Li, and Christopher V. Nicchitta. “GRP94 (gp96) and GRP94 N-terminal geldanamycin binding domain elicit tissue nonrestricted tumor suppression.” J Exp Med 196, no. 11 (December 2, 2002): 1447–59. https://doi.org/10.1084/jem.20020436.Full Text Link to Item
-
Fadel, Shaza A., Daniel A. Ozaki, and Marcella Sarzotti. “Enhanced type 1 immunity after secondary viral challenge in mice primed as neonates.” J Immunol 169, no. 6 (September 15, 2002): 3293–3300. https://doi.org/10.4049/jimmunol.169.6.3293.Full Text Link to Item
-
Cerasoli, D. M., G. Kelsoe, and M. Sarzotti. “CD4+Thy1- thymocytes with a Th-type 2 cytokine response.” Int Immunol 13, no. 1 (January 2001): 75–83. https://doi.org/10.1093/intimm/13.1.75.Full Text Link to Item
-
McKenna, K. C., M. Tsuji, M. Sarzotti, J. B. Sacci, A. A. Witney, and A. F. Azad. “gammadelta T cells are a component of early immunity against preerythrocytic malaria parasites.” Infect Immun 68, no. 4 (April 2000): 2224–30. https://doi.org/10.1128/IAI.68.4.2224-2230.2000.Full Text Link to Item
-
Fadel, S., and M. Sarzotti. “Cellular immune responses in neonates.” Int Rev Immunol 19, no. 2–3 (2000): 173–93. https://doi.org/10.3109/08830180009088504.Full Text Link to Item
-
Garcia, A. M., S. A. Fadel, S. Cao, and M. Sarzotti. “T cell immunity in neonates.” Immunol Res 22, no. 2–3 (2000): 177–90. https://doi.org/10.1385/IR:22:2-3:177.Full Text Link to Item
-
Butts, C., I. Zubkoff, D. S. Robbins, S. Cao, and M. Sarzotti. “DNA immunization of infants: potential and limitations.” Vaccine 16, no. 14–15 (1998): 1444–49. https://doi.org/10.1016/s0264-410x(98)00106-6.Full Text Link to Item
-
Sarzotti, M., T. A. Dean, M. P. Remington, C. D. Ly, P. A. Furth, and D. S. Robbins. “Induction of cytotoxic T cell responses in newborn mice by DNA immunization.” Vaccine 15, no. 8 (June 1997): 795–97. https://doi.org/10.1016/s0264-410x(96)00250-2.Full Text Link to Item
-
Sarzotti, M. “Immunologic tolerance.” Curr Opin Hematol 4, no. 1 (January 1997): 48–52. https://doi.org/10.1097/00062752-199704010-00008.Full Text Link to Item
-
Sarzotti, M. “Response: immunological tolerance.” Science 272, no. 5267 (June 7, 1996): 1408a. https://doi.org/10.1126/science.272.5267.1408a.Full Text Link to Item
-
Silverstein, A. M. “Immunological tolerance.” Science 272, no. 5267 (June 7, 1996): 1405–8. https://doi.org/10.1126/science.272.5267.1405a.Full Text Link to Item
-
Sarzotti, M., D. S. Robbins, and P. M. Hoffman. “Induction of protective CTL responses in newborn mice by a murine retrovirus.” Science 271, no. 5256 (March 22, 1996): 1726–28. https://doi.org/10.1126/science.271.5256.1726.Full Text Link to Item
-
Giese, N. A., R. T. Gazzinelli, J. K. Actor, R. A. Morawetz, M. Sarzotti, and H. C. Morse. “Retrovirus-elicited interleukin-12 and tumour necrosis factor-alpha as inducers of interferon-gamma-mediated pathology in mouse AIDS.” Immunology 87, no. 3 (March 1996): 467–74. https://doi.org/10.1046/j.1365-2567.1996.492569.x.Full Text Link to Item
-
Robbins, D. S., M. P. Remington, M. Sarzotti, D. St Louis, and P. M. Hoffman. “Immunogenic determinants of a neuropathogenic murine leukemia virus.” J Virol 69, no. 11 (November 1995): 6847–51. https://doi.org/10.1128/JVI.69.11.6847-6851.1995.Full Text Link to Item
-
Coppenhaver, D. H., I. P. Singh, M. Sarzotti, H. B. Levy, and S. Baron. “Treatment of intracranial alphavirus infections in mice by a combination of specific antibodies and an interferon inducer.” Am J Trop Med Hyg 52, no. 1 (January 1995): 34–40. https://doi.org/10.4269/ajtmh.1995.52.34.Full Text Link to Item
-
Sarzotti, M., T. A. Dean, M. Remington, and P. M. Hoffman. “Ultraviolet-light-inactivated Cas-Br-M murine leukemia virus induces a protective CD8+ cytotoxic T lymphocyte response in newborn mice.” Aids Res Hum Retroviruses 10, no. 12 (December 1994): 1695–1702. https://doi.org/10.1089/aid.1994.10.1695.Full Text Link to Item
-
Sarzotti, M., M da P. Gomes, and P. M. Hoffman. “IFN-gamma production in response to neuropathogenic Cas-Br-M murine leukemia virus infection.” Viral Immunol 6, no. 3 (1993): 207–17. https://doi.org/10.1089/vim.1993.6.207.Full Text Link to Item
-
Sarzotti, M., V. Kumar, M. Bennett, and G. Kelsoe. “Cloning of murine splenic T lymphocytes and natural killer (NK) cells on filter paper discs: detection of a novel NK/T phenotype.” Eur J Immunol 21, no. 3 (March 1991): 635–41. https://doi.org/10.1002/eji.1830210315.Full Text Link to Item
-
Singh, I. P., D. H. Coppenhaver, M. Sarzotti, P. Sriyuktasuth, J. Poast, H. B. Levy, and S. Baron. “Postinfection therapy of arbovirus infections in mice.” Antimicrob Agents Chemother 33, no. 12 (December 1989): 2126–31. https://doi.org/10.1128/AAC.33.12.2126.Full Text Link to Item
-
Sarzotti, M., D. H. Coppenhaver, I. P. Singh, J. Poast, and S. Baron. “The in vivo antiviral effect of CL246,738 is mediated by the independent induction of interferon-alpha and interferon-beta.” J Interferon Res 9, no. 3 (June 1989): 265–74. https://doi.org/10.1089/jir.1989.9.265.Full Text Link to Item
-
Sarzotti, M., G. R. Klimpel, and S. Baron. “Long-term killing of natural killer-resistant target cells by interferon-alpha-, interferon-gamma-, and interleukin-2-activated natural killer cells.” Nat Immun Cell Growth Regul 8, no. 2 (1989): 66–75.Link to Item
-
Stanton, G. J., R. E. Lloyd, M. Sarzotti, and J. E. Blalock. “Protection of mice from Semliki Forest virus infection by lymphocytes treated with low levels of interferon.” Mol Biother 1, no. 6 (1989): 305–10.Link to Item
-
Sarzotti, M., S. Baron, and G. R. Klimpel. “EL-4 metastases in spleen and bone marrow suppress the NK activity generated in these organs.” Int J Cancer 39, no. 1 (January 15, 1987): 118–25. https://doi.org/10.1002/ijc.2910390121.Full Text Link to Item
-
Sarzotti, M., S. Baron, S. K. Tyring, and G. R. Klimpel. “Interferon-mediated protection of B16 melanoma cells from cytotoxicity by activated macrophages.” Cell Immunol 100, no. 1 (June 1986): 280–87. https://doi.org/10.1016/0008-8749(86)90028-6.Full Text Link to Item
-
Hughes, T. K., M. Sarzotti-Kelsoe, and S. Baron. “Tumor cell cytolysis by interferon-γ treated mononuclear leukocytes: Requirement for the continuous presence of interferon during cytolysis.” Ircs Medical Science 14, no. 9 (January 1, 1986): 892–93.
-
Klimpel, G. R., M. Sarzotti, V. E. Reyes, and K. D. Klimpel. “Characterization of cytotoxic cells generated from in vitro cultures of murine bone marrow cells.” Cell Immunol 92, no. 1 (April 15, 1985): 1–13. https://doi.org/10.1016/0008-8749(85)90059-0.Full Text Link to Item
-
Sarzotti, M., G. R. Klimpel, and S. Baron. “EL-4 metastases to lymphoid organs correlate with lack of local NK activity.” Federation Proceedings 44, no. 3 (January 1, 1985).
-
Sarzotti, M., S. Landolfo, and F. Dianzani. “Immune (gamma) interferon production by a murine T cell lymphoma: requirements for macromolecular synthesis and lack of relationship with cell cycle.” Infect Immun 41, no. 2 (August 1983): 624–30. https://doi.org/10.1128/iai.41.2.624-630.1983.Full Text Link to Item
-
Forni, G., M. Giovarelli, M. Sarzotti, and A. C. Whitmore. “Rous sarcoma virus-induced tumours in mice. II. Contribution of H-2 and non-H-2 alloantigen barriers to tumour immunogenicity in vivo.” J Immunogenet 10, no. 3 (June 1983): 209–20. https://doi.org/10.1111/j.1744-313x.1983.tb00797.x.Full Text Link to Item
-
Landolfo, S., E. Balzi, M. Sarzotti, A. Negro-Ponzi, and B. Arnold. “Some characteristics of mouse immune (y) interferon produced by a T-lymphoma cell line.” Microbiologica 6, no. 2 (April 1983): 101–6.Link to Item
-
Sarzotti, M., M. Giovarelli, and G. Forni. “Interferon production in mixed cultures of murine leukocytes and syngeneic L1210 leukemia cells.” Boll Ist Sieroter Milan 61, no. 3 (1982): 218–24.Link to Item
-
Sarzotti, M., and S. Landolfo. “[Characteristics of cells producing immune interferon].” G Batteriol Virol Immunol 74, no. 7–12 (1981): 224–28.Link to Item
-
-
Book Sections
-
D’Souza, P., J. H. Cox, G. Ferrari, N. T. Kunwar, V. Polonis, and M. Sarzotti-Kelsoe. “Endpoint Assays in HIV-1 Vaccine Trials: Functioning in a Good Laboratory Practices Environment.” In Validation of Cell-Based Assays in the GLP Setting: A Practical Guide, 239–75, 2008. https://doi.org/10.1002/9780470987810.ch14.Full Text
-
-
Other Articles
-
Mascola, John R., Patricia D’Souza, Peter Gilbert, Beatrice H. Hahn, Nancy L. Haigwood, Lynn Morris, Christos J. Petropoulos, Victoria R. Polonis, Marcella Sarzotti, and David C. Montefiori. “Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines.” J Virol, August 2005. https://doi.org/10.1128/JVI.79.16.10103-10107.2005.Full Text Link to Item
-
-
Conference Papers
-
Sarzotti-Kelsoe, M., X. Daniell, C. A. Todd, M. Bilska, A. Martelli, C. LaBranche, L. G. Perez, et al. “Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells.” In Journal of Immunological Methods, 2014.Open Access Copy
-
Ferrari, G., J. Cox, A. Garcia, W. Rountree, C. DeCastro, R. Louzao, B. Liebl, et al. “Development of CAVD/EQAPOL Long-Term PBMC Repository ('07-'10) @ DUMC; T-Cell Functionality as Measured by ELISpot and Flow Cytometry Is Maintained Ov.” In Aids Research and Human Retroviruses, 27:A55–A55. MARY ANN LIEBERT INC, 2011.Link to Item
-
Hu, X., K. Hong, C. Zhao, Y. Zheng, L. Ma, Y. Ruan, M. Sarzotti-Kelsoe, D. C. Montafiori, and Y. Shao. “Profiles of neutralizing antibody responses in chronically HIV-1 clade B' infected treatment-naive former plasma donors in China.” In Aids Research and Human Retroviruses, 26:A44–46. MARY ANN LIEBERT INC, 2010.Link to Item
-
Todd, C. A., X. Yu, D. A. Ozaki, K. M. Greene, H. Gao, B. Wood, M. Wang, P. Gilbert, D. C. Montefiori, and M. Sarzotti-Kelsoe. “P15-04. Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells.” In Retrovirology, Vol. 6, 2009. https://doi.org/10.1186/1742-4690-6-S3-P205.Full Text
-
Lopalco, L., A. Parri, S. Nyoka, G. Sherman, M. Sarzotti-Kelsoe, and C. Gray. “Pattern of HIV-1-gp41 Binding and Neutralizing Antibodies in Subtype C Infected Women and in their HIV-1-Seronegative Neonates.” In Aids Research and Human Retroviruses, 24:45–45. MARY ANN LIEBERT INC, 2008.Link to Item
-
Nyoka, S., G. Sherman, M. Sarzotti-Kelsoe, D. Ozaki, Z. Makatini, and C. M. Gray. “Perturbations of the Vb-T Cell Repertoire in HIV Uninfected Neonates Born to HIV-1 Subtype C Infected Mothers: Evidence for T Cell Priming in Utero.” In Aids Research and Human Retroviruses, 24:124–124. MARY ANN LIEBERT INC, 2008.Link to Item
-
Parri, A., E. Begaud, G. Pancino, G. Sherman, C. M. Gray, M. Sarzotti-Kelsoe, L. Diomede, C. Alberti, and L. Lopalco. “Profile of HIV-1-env Binding and Neutralizing Antibodies in Subtype C, A and B Infected Women.” In Aids Research and Human Retroviruses, 24:42–42. MARY ANN LIEBERT INC, 2008.Link to Item
-
Tomfohr, J., M. He, L. Cowell, M. Sarzotti-Kelsoe, M. L. Markert, and T. B. Kepler. “T cell competition and repertoire diversity: the roles of TCR-specific and non-specific resource limitation determined through multivariate data analysis and computational modeling.” In Faseb Journal, 18:A798–A798. FEDERATION AMER SOC EXP BIOL, 2004.Link to Item
-
-
- Teaching & Mentoring
-
Advising & Mentoring
-
1997 Master Thesis Mentor for Ira Zubkoff, Dept. of Microbiology and Immunology, University of Maryland at Baltimore, School of Medicine
1997-2000 Post-doctoral Mentor for Dr. Shui Cao, Dept. of Microbiology and Immunology, University of Maryland at Baltimore, School of Medicine and Dept. of Immunology, Duke University Medical Center
2000 Master Thesis Mentor for Ana M. Garcia, Dept. of Immunology, Duke University Medical Center
2003 Ph.D. Dissertation Mentor; Shaza Fadel, Dept. of Immunology, Duke University Medical Center
2003 M.D., Ph.D. Dissertation Co-Mentor; Julie Baker-LePain, Dept. of Cell Biology, Duke University Medical Center
2004 Ph.D. Dissertation Committee Advisor; Deborah Ruhl, Dept. of Immunology, Duke University Medical Center
2006 Master Dissertation Committee Advisor; Rachel Lovinghood, Dept. of Cell Biology, Duke University Medical Center
2008 Master Dissertation Committee Advisor; Stephina N. Nyoka, University of Witwatersrand, Johannesburg, South Africa
2008 Ph.D. Dissertation Committee Advisor; Bernice Ho, Dept. of Cell Biology, Duke University Medical Center
2013-present Ph.D. Dissertation Committee Advisor; Saintedym Wills, Dept. of Immunology, Duke University Medical Center
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.